Arbutus Biopharma Corp (FRA:I9DN)
€ 3.448 -0.098 (-2.76%) Market Cap: 687.51 Mil Enterprise Value: 558.40 Mil PE Ratio: 0 PB Ratio: 5.95 GF Score: 50/100

Q3 2019 Arbutus Biopharma Corp Earnings Call Transcript

Nov 06, 2019 / 01:45PM GMT
Release Date Price: €1.31 (+3.97%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation 2019 Third Quarter Financial Results and Corporate Update. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Pam Murphy, with Investor Relations.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Good morning. On the call from the Arbutus Executive Team are Bill Collier, President and Chief Executive Officer; Dave Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer. Bill will begin with a review of corporate objectives and clinical developments, followed by Dave, who will provide a review of the company's third quarter financial results. We'll then open up the call for Q&A. Gaston and Mike will be available to address research and clinical development-related questions.

Before we begin, we'd like to remind you that some of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot